Intrexon (NYSE:XON) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report released on Sunday.
Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Intrexon from a “hold” rating to a “sell” rating in a report on Monday, October 16th. JMP Securities reissued an “outperform” rating and issued a $42.00 target price on shares of Intrexon in a report on Thursday, October 5th. Stifel Nicolaus raised their price target on shares of Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Northland Securities restated a “buy” rating and issued a $21.00 price target on shares of Intrexon in a research note on Friday, November 10th. Finally, Griffin Securities restated a “buy” rating and issued a $55.00 price target on shares of Intrexon in a research note on Friday, October 6th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $38.50.
Intrexon (NYSE:XON) opened at $11.52 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. Intrexon has a 1-year low of $10.26 and a 1-year high of $26.99. The company has a market cap of $1,390.70, a PE ratio of -10.29 and a beta of 1.33.
Institutional investors and hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in shares of Intrexon by 2,031.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares in the last quarter. Steward Partners Investment Advisory LLC acquired a new stake in shares of Intrexon in the 3rd quarter valued at approximately $121,000. Federated Investors Inc. PA acquired a new stake in shares of Intrexon in the 2nd quarter valued at approximately $172,000. SG Americas Securities LLC acquired a new stake in shares of Intrexon in the 3rd quarter valued at approximately $139,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Intrexon in the 2nd quarter valued at approximately $212,000. Institutional investors own 77.45% of the company’s stock.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/02/valuengine-downgrades-intrexon-xon-to-strong-sell.html.
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.